GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Impel Pharmaceuticals Inc (FRA:84P) » Definitions » EV-to-EBITDA

Impel Pharmaceuticals (FRA:84P) EV-to-EBITDA : -1.63 (As of Jun. 03, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Impel Pharmaceuticals EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Impel Pharmaceuticals's enterprise value is €105.20 Mil. Impel Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was €-64.39 Mil. Therefore, Impel Pharmaceuticals's EV-to-EBITDA for today is -1.63.

The historical rank and industry rank for Impel Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:

FRA:84P' s EV-to-EBITDA Range Over the Past 10 Years
Min: -2.58   Med: -1.28   Max: -0.19
Current: -1.67

During the past 4 years, the highest EV-to-EBITDA of Impel Pharmaceuticals was -0.19. The lowest was -2.58. And the median was -1.28.

FRA:84P's EV-to-EBITDA is ranked worse than
100% of 452 companies
in the Biotechnology industry
Industry Median: 9.47 vs FRA:84P: -1.67

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-03), Impel Pharmaceuticals's stock price is €0.0405. Impel Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was €-2.931. Therefore, Impel Pharmaceuticals's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Impel Pharmaceuticals EV-to-EBITDA Historical Data

The historical data trend for Impel Pharmaceuticals's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Impel Pharmaceuticals EV-to-EBITDA Chart

Impel Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22
EV-to-EBITDA
- - -2.00 -0.97

Impel Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.98 -0.97 -0.62 -0.87 -1.81

Competitive Comparison of Impel Pharmaceuticals's EV-to-EBITDA

For the Biotechnology subindustry, Impel Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Impel Pharmaceuticals's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Impel Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Impel Pharmaceuticals's EV-to-EBITDA falls into.



Impel Pharmaceuticals EV-to-EBITDA Calculation

Impel Pharmaceuticals's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=105.201/-64.389
=-1.63

Impel Pharmaceuticals's current Enterprise Value is €105.20 Mil.
Impel Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-64.39 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Impel Pharmaceuticals  (FRA:84P) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Impel Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0405/-2.931
=At Loss

Impel Pharmaceuticals's share price for today is €0.0405.
Impel Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.931.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Impel Pharmaceuticals EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Impel Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Impel Pharmaceuticals (FRA:84P) Business Description

Traded in Other Exchanges
Address
201 Elliott Avenue West, Suite 260, Seattle, WA, USA, 98119
Impel Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. The company is developing an approach to drug delivery that administers specific formulations of drugs deep into the vascular-rich upper nasal space, a gateway for therapeutic administration of a versatile range of molecules and formulations.

Impel Pharmaceuticals (FRA:84P) Headlines

No Headlines